LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

34.69 -5.58

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.52

Massimo

36.72

Metriche Chiave
By Trading Economics
Entrata	-5M -128M
Vendite	6.8M 11M
EPS	-1.23
Margine di Profitto	-1,191.029
Dipendenti	594
EBITDA	-18M -139M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+133.89% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-496M 3.9B
Apertura precedente	40.27
Chiusura precedente	34.69

Notizie sul Sentiment di mercato

By Acuity

84%

16%

321 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 mag 2026, 23:10 UTC

Azioni calde

Stocks to Watch: Agilysys, XP

18 mag 2026, 18:44 UTC

I principali Market Mover

Claritev Shares Recover After Comments About DOJ

18 mag 2026, 23:55 UTC

Utili

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mag 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

18 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mag 2026, 23:37 UTC

Discorsi di Mercato

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mag 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mag 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

18 mag 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

18 mag 2026, 20:25 UTC

Utili

Correct: XP 1Q Total Client Assets BRL1.53T

18 mag 2026, 20:23 UTC

Utili

XP 1Q Total Client Assets BRL1.53B

18 mag 2026, 20:19 UTC

Utili

XP 1Q Adj EPS BRL2.49 >XP

18 mag 2026, 20:19 UTC

Utili

XP 1Q Rev BRL4.73B >XP

18 mag 2026, 19:10 UTC

Discorsi di Mercato

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mag 2026, 19:00 UTC

Utili

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mag 2026, 18:52 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mag 2026, 18:17 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mag 2026, 17:22 UTC

Discorsi di Mercato

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mag 2026, 16:57 UTC

Acquisizioni, Fusioni, Takeovers

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mag 2026, 16:57 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

18 mag 2026, 16:57 UTC

Discorsi di Mercato

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mag 2026, 16:54 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Doesn't Set Out Financial Details of Deal

18 mag 2026, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mag 2026, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mag 2026, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mag 2026, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Vinci Buys Canada's Modern Group of Companies

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

133.89% in crescita

Previsioni per 12 mesi

Media 86 USD 133.89%

Alto 97 USD

Basso 67 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

321 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.